On our screens:Cheap stocks by free cash flow yield
Is the price fair?
What TMDX's price assumes
TransMedics Group, Inc. trades at 20.2× earnings against 30.9× for the median Medical Devices name, cheaper than its own group.
20.2
Trailing P/E · Medical Devices median 30.9 · cheaper than the typical name in its group
- Price / sales
- 5.66
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.6%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +4.1%
Growth the price implies · The price pays for +4.1% free cash flow growth a year for a decade; revenue has grown +75% a year over the last three.
Details›
- Price / book2026-Q1
- 7.28
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $151M
- Market capitalisation
- $2.69B
- 3-year revenue growth
- +75%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.